secwatch.observer — SEC 8-K summary
======================================

Issuer:     TG THERAPEUTICS, INC. (TGTX)
CIK:        0001001316
Form:       8-K
Filed at:   2024-06-17T23:59:59+00:00
Accession:  0001437749-24-020510
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 5.02, 5.07, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TG Therapeutics shareholders approve share increase and incentive plan amendment at 2024 annual meeting
--------------------------------------------------------------------------------

- Shareholders approved increasing authorized common stock from 175M to 190M (73.8M for, 36.3M against).
- Shareholders approved amendment to 2022 Incentive Plan removing full-value award limit (66.7M for, 8.6M against).
- Two director nominees (Yann Echelard, Daniel Hume) each received less than 50% of votes cast for election.
- Advisory say-on-pay proposal passed with 55.6% support (42.3M for, 31.0M against).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001316/000143774924020510/0001437749-24-020510-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001316/000143774924020510/tgtx20240614_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-020510

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer